

Quarterly HOTLINE: Effective **November 12, 2018**

**New Test**    **3000601**    **Antinuclear Antibody (ANA) with HEp-2 Substrate, IgG by IFA with Reflex by Pattern**    **ANA AB PAT**



**Additional Technical Information**

**Methodology:** Semi-Quantitative Indirect Fluorescent Antibody/Qualitative Enzyme-Linked Immunosorbent Assay/Semi-Quantitative Enzyme-Linked Immunosorbent Assay/Semi-Quantitative Multiplex Bead Assay/Qualitative Immunoblot

**Performed:** Sun-Sat

**Reported:** 1-8 days

**Specimen Required:** Collect: Serum Separator Tube (SST).

Specimen Preparation: Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.6 mL)

Storage/Transport Temperature: Refrigerated

Unacceptable Conditions: Non-serum specimens. Contaminated, grossly hemolyzed, heat-inactivated, severely lipemic specimens.

Stability (collection to initiation of testing): After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles)

**Reference Interval:**

Test Number	Components	Reference Interval	
3000082	Antinuclear Antibody (ANA), HEp-2, IgG	Less than 1:80	
2003040	PM/Scl-100 Antibody, IgG by Immunoblot	Negative	
2012173	Fibrillarin (U3 RNP) Antibody, IgG	Negative	
0050215	Double-Stranded DNA (dsDNA) Antibody, IgG by ELISA with Reflex to dsDNA Antibody, IgG by IFA	<b>Test Number</b>	<b>Components</b>
			Double-Stranded DNA (dsDNA) Antibody, IgG by ELISA
		2002693	Double-Stranded DNA (dsDNA) Antibody, IgG by IFA (using Crithidia luciliae)
			None Detected.
			Less than 1:10
2005287	Chromatin Antibody, IgG	19 Units or less	Negative
		20-60 Units	Moderate Positive
		61 Units or greater	Strong Positive
2001601	RNA Polymerase III Antibody, IgG	19 Units or less	Negative
		20-39 Units	Weak Positive
		40-80 Units	Moderate Positive
		81 Units or greater	Strong Positive
0050599	Scleroderma (Scl-70) (ENA) Antibody, IgG	29 AU/mL or less	Negative
		30-40 AU/mL	Equivocal
		41 AU/mL or greater	Positive
0050470	RNP (U1) (Ribonucleic Protein) (ENA) Antibody, IgG	29 AU/mL or less	Negative
		30-40 AU/mL	Equivocal
		41 AU/mL or greater	Positive
0050085	Smith (ENA) Antibody, IgG	29 AU/mL or less	Negative
		30-40 AU/mL	Equivocal
		41 AU/mL or greater	Positive
2012074	SSA 52 and 60 (Ro) (ENA) Antibodies, IgG	<b>Test Number</b>	<b>Components</b>
			SSA-52 (Ro52) (ENA) Antibody, IgG
			SSA-60 (Ro60) (ENA) Antibody, IgG
			29 AU/mL or Less: Negative 30-40 AU/mL: Equivocal 41 AU/mL or greater: Positive
			29 AU/mL or Less: Negative 30-40 AU/mL: Equivocal 41 AU/mL or greater: Positive
0050692	SSB (La) (ENA) Antibody, IgG	29 AU/mL or less	Negative
		30-40 AU/mL	Equivocal
		41 AU/mL or greater	Positive

**Interpretive Data:** Refer to report.

Quarterly HOTLINE: Effective **November 12, 2018**

**Note:** The Antinuclear Antibody (ANA), IgG by IFA with Reflex by IFA Pattern begins with Nuclear Antibody (ANA) by IFA, IgG. Depending on findings, one or more reflexive tests may be required. Tests added may include Double-Stranded DNA (dsDNA) Antibody, IgG by ELISA; Double-Stranded DNA (dsDNA) Antibody, IgG by IFA (using Crithidia luciliae); Chromatin Antibody, IgG; RNP (U1) (Ribonucleic Protein) (ENA) Antibody, IgG; Fibrillarin (U3 RNP) Antibody, IgG; Smith (ENA) Antibody, IgG; SSA 52 (Ro) (ENA) Antibody, IgG; SSA 60 (Ro) (ENA) Antibody, IgG; SSB (La) (ENA) Antibody, IgG; Scleroderma (Scl-70) (ENA) Antibody, IgG; PM/Scl-100 Antibody, IgG, by Immunoblot; and/or RNA Polymerase III Antibody, IgG. Additional charges apply.

ANA determined by indirect fluorescence assay (IFA) use HEp-2 substrate and IgG-specific conjugate at a screening dilution of 1:80. If positive, patterns reported include homogeneous, speckled, centromere, nucleolar, nuclear dots, or cytoplasmic. All positive results are reported with endpoint titers.

**CPT Code(s):** 86039; if homogenous or speckled pattern add 86235 x6, 86225, and 83516; if reflexed add 86256; If nucleolar pattern add 86235 x3 and 83516

New York DOH Approved.

**HOTLINE NOTE:** Refer to the Test Mix Addendum for interface build information.